Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28169091 | 0.87 | SIGMAR1 (0.43) | SMN1; SMN2HTR2AMAOAMAOBSIGMAR1 | |
| SCHEMBL470 | 0.85 | — | — | |
| SCHEMBL27610715 | 0.83 | ALDH1A1 (0.52) | ALDH1A1HPGDALOX15ALOX12CASP1 | |
| SCHEMBL22092377 | 0.83 | ALDH1A1 (0.52) | ALDH1A1HPGDALOX15ALOX12CASP1 | |
| Ethylene SCHEMBL28196223 | 0.83 | ALDH1A1 (0.52) | ALDH1A1HPGDALOX15ALOX12CASP1 | |
| Hydrochloric Acid SCHEMBL10398514 | 0.83 | ALDH1A1 (0.52) | ALDH1A1HPGDALOX15ALOX12CASP1 | |
| SCHEMBL6737980 | 0.81 | CALM1 (0.39) | ALDH1A1HPGDALOX15ALOX12CASP1 | |
| SCHEMBL9146773 | 0.80 | — | — | |
| SCHEMBL5537656 | 0.80 | MAOB (0.56) | ALDH1A1HPGDALOX15ALOX12CASP1 | |
| SCHEMBL28294218 | 0.79 | ALDH1A1 (0.44) | ALDH1A1HPGDALOX15ALOX12CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0937040-B1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2004-07-21 | — | — | EP | claimed |
| US-6730683-B2 | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses | SMITHKLINE BEECHAM CORPORATION | 2004-05-04 | — | — | US | claimed |
| US-6011155-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-01-04 | — | — | US | claimed |
| EP-0937040-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 1999-08-25 | — | — | EP | claimed |
| WO-1998019998-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 1998-05-14 | — | — | WO | claimed |
| CN-108697606-A | Personal care composition and the method for using such composition | 罗地亚经营管理公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-106715483-B | Ethene polymers and stretch forming thing and polyvinyl manufacture method obtained from being stretched | 旭化成株式会社 | 2018-04-20 | — | — | CN | disclosed |
| CN-105229108-B | Matrix polymer for hot-melt adhesive and hot-melt adhesive | 出光兴产株式会社 | 2018-03-09 | — | — | CN | disclosed |
| CN-104781291-B | Propylene polymer and hot-melt adhesive | 出光兴产株式会社 | 2018-02-13 | — | — | CN | disclosed |
| CN-106715483-A | Ethylene polymer, shaped object obtained by stretching same, and process for producing ethylene polymer | 旭化成株式会社 | 2017-05-24 | — | — | CN | disclosed |
| CN-106661065-A | Crystal of cyclic phosphonic acid sodium salt and method for producing same | 大塚化学株式会社 | 2017-05-10 | — | — | CN | disclosed |
| US-20100210579-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | GILEAD PALO ALTO, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| EP-0937040-B1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2004-07-21 | — | — | EP | disclosed |
| US-6730683-B2 | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses | SMITHKLINE BEECHAM CORPORATION | 2004-05-04 | — | — | US | disclosed |
| WO-2003038123-A2 | METHODS TO TREAT DIABETES AND RELATED CONDITIONS BASED ON POLYMORPHISMS IN THE TCF1 GENE | NOVARTIS AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| US-6335340-B1 | REACTING POLYMER BOUND 2-THIOPYRIMIDINE-4-YL IMINE WITH AN ISONITRILE; OXIDATION TO SULFONE OR SULFOXIDE TO RELEASE; AMINATION; ADMINISTERING AS CYTOKINE, INTERLEUKIN, AND TUMOR NECROSIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6124305-A | TREATING NON-INSULIN DEPENDENT DIABETES MELLITUS | NOVARTIS AG (CH) | 2000-09-26 | — | — | US | disclosed |
| US-6011155-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-01-04 | — | — | US | disclosed |
| EP-0937040-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998019998-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210579-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | ADORA1, ADORA2A, GPR119 | ALDH1A1 358/4885HPGD 3085/4885ALOX15 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.